Despite the relative lack of effect of zileuton on allergen
responses, in a 4 week placebo-controlled trial in
patients with mild to moderate asthma, it improved airway
function and symptoms. At the highest dose of 2.4
gm.day-1, there were a mean increase in FEV1 of 13.4%,
a decrease in b-agonist usage by 24%, an improvement
in morning peak expiratory flow rate of 10%, a decrease
in overall symptom scores of 37%, and a decrease in
urinary leukotriene excretion by 39% [72]. There were
no significant side-effects reported. Another long-term
study with zileuton examined its protective effect against
cold, dry air-induced bronchoconstriction after 13 weeks
of pretreatment. The protection observed was found to
persist for up to 10 days after discontinuation of zileuton,
which has a half-life of only 2.3 h [74].
Despite the relative lack of effect of zileuton on allergen
responses, in a 4 week placebo-controlled trial in
patients with mild to moderate asthma, it improved airway
function and symptoms. At the highest dose of 2.4
gm.day-1, there were a mean increase in FEV1 of 13.4%,
a decrease in b-agonist usage by 24%, an improvement
in morning peak expiratory flow rate of 10%, a decrease
in overall symptom scores of 37%, and a decrease in
urinary leukotriene excretion by 39% [72]. There were
no significant side-effects reported. Another long-term
study with zileuton examined its protective effect against
cold, dry air-induced bronchoconstriction after 13 weeks
of pretreatment. The protection observed was found to
persist for up to 10 days after discontinuation of zileuton,
which has a half-life of only 2.3 h [74].
การแปล กรุณารอสักครู่..
